// App-Quantinova.ai

TPS9597 : Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).

Researchers

Presenter

  • Ari M. Vanderwalde

Principal Investigators

  • Michaella Latkovic-Taber

  • Siwen Hu-Lieskovan

  • Kenneth F. Grossmann

  • Jeffrey Alan Sosman

  • Danae Campos

  • Michael Wu

  • Antoni Ribas

Medical Centers

  • Division of Hematology/Oncology, the University of Tennessee Health Science Center, West Cancer Center, Memphis, TN

  • SWOG Statistical Center, Seattle, WA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Northwestern University Medical Center, Chicago, IL

  • SWOG Operatons Office, San Antonio, TX

  • University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Programmed cell death protein 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Prospective

Phase

  • II

Study Id's

  • NCT03033576

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved